Promise Bio

The AI engine Fit Assessment

Beta

The company effectively leverages machine learning for biomarker discovery and therapeutic expansion, demonstrating a strong fit in the healthcare innovation space.

Blurb

Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins.

HQ Location

Tel Aviv-Yafo (Israel)

Founded

2023

Employees

1 - 10

Total funding raised

$8.30M

Last Funding Event

Grant, December 16, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification

Operator of an artificial intelligence-based healthcare platform intended to treat lingering diseases. The company specializes in harnessing complex artificial intelligence biomarker discovery technology to optimize personalized treatment plans and facilitate quality of care, enabling patients to get affordable treatment for chronic diseases and improve their health.